That turnaround on new FDA drug approvals? We’re right on schedule
We were due for a pretty good year on new drug approvals from the FDA, and so far the agency and the industry have been performing on schedule.
Last year at this time the FDA had recorded just 7 new drug OKs on the way to a miserable 22 new drug approvals for 2016. In a number of cases the anemic rate of approvals was fed by temporary reversals based on manufacturing snafus, a condition still acutely felt at AstraZeneca, which just had its second rejection on ZS-9.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.